Sottas's aging-signal theory and xLongevity's service
Sottas proposes that senescent-cell signals amplify mortality risk, while his company's related service still needs evidence of efficacy beyond a model and a cited 14-person infusion program.
An aging-signal theory and an xLongevity service
Pierre-Edouard Sottas, co-founder of xLongevity, a company that operates longevity clinics, proposes that signals from senescent cells sustain their own spread and accelerate the rise in mortality risk with age. His company is announcing a service designed to alter those signals. Eternal Search lists him in Sottas's profile in the Eternal Search investor section.
On October 20, the scientific journal Aging published Sottas's theoretical paper. He separates aging into accumulated cellular damage and the amplification of its effects through signals between cells. Senescent cells stop dividing but release inflammatory substances and membrane-bound sacs containing proteins and ribonucleic acid (RNA). His hypothesis is that these signals cause other cells to become senescent and release the same substances, creating a self-sustaining feedback loop. The immune system removes senescent cells, while stem cells renew tissues, keeping this process in check. He calls their combined ability to do this regenerative capacity and proposes that it declines with age.
In the computer model, reducing incoming damage has its greatest effect early in life. In old age, established feedback responds weakly to that intervention. Clearing senescent cells works best in old age, while increasing regenerative capacity suppresses senescence signals at any age. These are model results. xLongevity is announcing Systemic Signal Reset, a service with the stated aim of reducing signals that promote aging and increasing regenerative signals.
For infusions of cell culture fluid, the medium in which cells were grown, the paper cites only a pilot study co-authored by Sottas. After a 17-week program that included two infusions, the epigenetic age of 14 participants was an average of 2.7 years below baseline. This age estimate uses chemical marks on DNA, the molecule that stores genetic information. A change in that estimate alone does not establish how long someone will live. The result also applies to the entire program: the supplied data cannot isolate the contribution of the two infusions or establish a reduction in mortality risk.
Sottas develops the hypothesis, co-authored the study, and is connected to a company offering a service with a related aim. Those roles belong in an assessment of the evidence. Establishing the service's efficacy requires data on its own outcomes in humans; the computer model and the described 14-person program do not yet establish it.
Open the related Eternal Search page
Sources
[1] aging-us.com
[2] nature.com
[3] nature.com
[4] t.me
[5] doi.org
[6] doi.org
[7] pmc.ncbi.nlm.nih.gov
[8] frontiersin.org
This item was selected because Sottas is both the author of the theoretical paper and a co-founder of the company offering a related service. His Eternal Search page, listed in the investor section, gives readers a direct public entry point for inspecting the person behind the news without implying that Eternal Search has verified the theory or the treatment.